Enzene gets DCGI nod for biosimilar drug to treat haematological disorder
Tuesday, September 28, 2021, 7:12
The symptoms of this disorder ranges from mild skin bleeding and bruises to potentially fatal internal bleeding, such as in the gastrointestinal tract and the brain.
You can follow any responses to this entry through the
RSS 2.0 feed.